#news #biotech Recursion, targeting cancer, rare disease midstage tests, sets terms for $306M IPO

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Recursion, targeting cancer, rare disease midstage tests, sets terms for $306M IPO .Recursion, targeting cancer, rare disease midstage tests, sets terms for $306M IPO
badams
Tue, 04/13/2021 – 04:03

from FierceBiotech: Biotech https://ift.tt/3a7pAht